Last reviewed · How we verify
Humulin Insulin Mixtard
Humulin Insulin Mixtard is a fixed combination of rapid-acting and intermediate-acting insulin that replaces or supplements endogenous insulin to regulate blood glucose levels.
Humulin Insulin Mixtard is a fixed combination of rapid-acting and intermediate-acting insulin that replaces or supplements endogenous insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Humulin Insulin Mixtard |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Insulin combination (rapid-acting + intermediate-acting) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Mixtard contains a mixture of soluble (rapid-acting) insulin and isophane (intermediate-acting) insulin, allowing for both immediate postprandial glucose control and sustained basal coverage. The insulin binds to insulin receptors on muscle, fat, and liver cells, promoting glucose uptake and storage while inhibiting hepatic glucose production. This dual-action formulation provides convenient once or twice-daily dosing for diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (PHASE4)
- Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus (NA)
- Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
- Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes (PHASE4)
- Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands
- Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
- Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes (PHASE2)
- Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humulin Insulin Mixtard CI brief — competitive landscape report
- Humulin Insulin Mixtard updates RSS · CI watch RSS
- Ain Shams University portfolio CI